Compare LMND & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LMND | LIVN |
|---|---|---|
| Founded | 2015 | 1987 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.5B |
| IPO Year | 2020 | 2015 |
| Metric | LMND | LIVN |
|---|---|---|
| Price | $52.96 | $82.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 7 |
| Target Price | $70.86 | ★ $72.43 |
| AVG Volume (30 Days) | ★ 947.0K | 660.6K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.40 | N/A |
| EPS | N/A | ★ 2.33 |
| Revenue | ★ $737,900,000.00 | N/A |
| Revenue This Year | $65.20 | $9.79 |
| Revenue Next Year | $33.31 | $6.63 |
| P/E Ratio | ★ N/A | $34.40 |
| Revenue Growth | ★ 40.15 | N/A |
| 52 Week Low | $46.16 | $48.82 |
| 52 Week High | $99.90 | $85.76 |
| Indicator | LMND | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 46.71 | 57.99 |
| Support Level | $52.26 | $61.63 |
| Resistance Level | $54.40 | $85.52 |
| Average True Range (ATR) | 1.97 | 2.05 |
| MACD | 0.42 | 0.19 |
| Stochastic Oscillator | 53.10 | 84.01 |
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes. The company is using technology, data, artificial intelligence, contemporary design, and social impact to deliver delightful and affordable insurances. The Company operates in one report segment providing personal property and casualty insurance products within the United States and Europe, including the UK.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.